Pituitary ACTH hypersecretion
Drug research and approvals for pituitary ACTH hypersecretion: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 12 studies of pituitary ACTH hypersecretion are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 12
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal…NCT07920198 · Not reported · Azienda Ospedaliero-Universitaria di Modena · starts Jul 9, 2026
- Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph…NCT07463625 · Not reported · Hospices Civils de Lyon · starts Nov 23, 2023
- FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing DiseaseNCT07460232 · Early Phase 1 · Mayo Clinic · starts Apr 27, 2026
- Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's…NCT07335315 · Not reported · Mayo Clinic · starts Jun 19, 2024
- Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CTNCT06962202 · Not reported · Post Graduate Institute of Medical Education and Research, Chandigarh · starts Aug 15, 2022
- Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseNCT05971758 · Phase 2 · University of California, Los Angeles · starts Jan 16, 2025
- DDAVP for Pituitary AdenomaNCT04569591 · Not applicable · National Institute of Neurological Disorders and Stroke (NINDS) · starts Mar 9, 2026
- Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)NCT04543253 · Not reported · Mayo Clinic · starts Jul 25, 2019
- Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid DisordersNCT04374721 · Not applicable · University of Roma La Sapienza · starts Jul 4, 2018
Approved 2
- PasireotideSomatostatin receptor 5 agonist
- OsilodrostatCytochrome P450 11B1 inhibitor
Phase 3 2
- MifepristoneGlucocorticoid receptor antagonist
- LevoketoconazoleCytochrome P450 11B1 inhibitor
Phase 2 6
- SeliciclibCyclin-dependent kinase 2 inhibitor
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- VorinostatHistone deacetylase 1 inhibitor
- CabergolineDopamine D2 receptor agonist
- FimepinostatPI3-kinase p110-delta subunit inhibitor
- AZD-401711-beta-hydroxysteroid dehydrogenase 1 inhibitor
Phase 1 or earlier 1
- BexaroteneRetinoid X receptor agonist
How its trials ended
51 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 63% met their primary endpoint, 0% missed it and 38% stopped early.
- Completed, result not reported1631%
- Ongoing1325%
- Met its primary endpoint1020%
- Status unknown612%
- Stopped: other or unclear36%
- Stopped: funding24%
- Stopped: enrollment or feasibility12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA